Resource Library

Technology alone won't get you where you want to go. And that's why we won't ever just offer technology.

Filter by

Resource type

Application Note
Article
Brochure
Case Study
eBook
Example Customer Report
Flyer
Primary Literature
Scientific Brief
Scientific Poster/Poster Presentation
Webinar/Presentation

Application

Virus-like Particles
Cell Based Assays
Cell Line Development
Cell Therapy
CRISPR/Gene Editing
Protein Production
Stem Cells
Vaccines
Viral Vectors

Cell type

B Cells
Cancer Cell Lines
Cardiomyocytes
CHO
Dendritic Cells
Fibroblasts
HEK293
HSPCs
Insect Cell Lines (S2/Sf9/Sf21)
ion channels
iPSCs
Keratinocytes
MSCs
Neurons
NK Cells
NPCs/NSCs
Other Mammalian Cell Lines
PBMCs
T Cells

Thumbnail for the poster of Production of Assay-Ready-Cells Ion Channels

Scientific Poster/Poster Presentation

Cell Based Assays

Cell Line Development

Stem Cells

HEK293

ion channels

MaxCyte Electroporation Enables the Production of Assay-Ready Cells Suitable for Ion Channel Studies

In this study, we show scalable, efficient transfection in a variety of cell lines and stem cells and present case studies demonstrating the suitability of assay-ready cells as an alternative to stable cell lines for ion channel research, assay development and drug discovery.

Scientific Brief

Cell Therapy

CRISPR/Gene Editing

SeQure DX™ Risk Assessment Services Align with FDA Guidance for Gene-Edited Human Gene Therapy Products

Our SeQure DX screening assays offer early insights into on- and off-target editing, addressing FDA and other regulatory expectations during guide design to reduce risk, streamline development and accelerate your path to the clinic.

Article

Cell Therapy

Gene Therapy

Rethinking Partnerships in Cell & Gene Therapy—How MaxCyte’s Business Model Drives Real Results

In the fast-moving world of cell and gene therapy (CGT), technology alone isn’t enough. We sat down with Sean Menarguez, senior director of business development at MaxCyte, to discuss how the company’s unique partnership model is helping developers accelerate progress, reduce risk and bring transformative therapies to market faster.

Optimizing CRISPR-Cas-mediated knockin poster thumbnail

Scientific Poster/Poster Presentation

CRISPR/Gene Editing

TCR/CAR T

T Cells

Optimizing CRISPR/Cas-Mediated CAR Knockin in Primary Human T Cells Using MaxCyte Electroporation

MaxCyte electroporation optimized CAR knockin to enable stable expression of tumor-targeting receptors in human T cells, while maintaining high cell viabilities and functionality.

Webinar/Presentation

CRISPR/Gene Editing

CAR T

Combining CRISPR & Transposon-Based Technologies for Improved sdAb-Based CAR T Therapies

Watch how a streamlined, one-step process for the generation of universal CAR T cells can reduce costs and accelerate clinical translation, while maintaining potency and durability in hematological malignancy models.

Video thumbnail for 2025 ASGCT presentation on optimizing transposons

Scientific Poster/Poster Presentation

Webinar/Presentation

Cell Therapy

T Cells

Scalable Electroporation Optimizes Transposon Delivery in CAR T Cell Manufacturing Workflows

MaxCyte researcher Max Van Buskirk discusses how scalable electroporation can enhance transposon delivery in CAR T cell manufacturing workflows.

Thumbnail for Optimizing CRISPR/Cas-mediated CAR Knockin in Primary Human T Cells Using MaxCyte presentation

Scientific Poster/Poster Presentation

Webinar/Presentation

Cell Therapy

CRISPR/Gene Editing

T Cells

MaxCyte Electroporation Enables CRISPR/Cas-Mediated CAR Knockin in Primary Human T cells

MaxCyte scientist Ashley Strickland-Dietz presents on protocols to improve non-viral engineering of CAR T cells, focusing on primary human T cells.

Video thumbnail for 2025 ASGCT presentation on optimizing VLP manufacturing

Scientific Poster/Poster Presentation

Webinar/Presentation

Virus-like Particles

CRISPR/Gene Editing

Gene Editing

Primary Cells

HEK293

T Cells

Optimizing VLP Manufacturing for Gene Editing by GMP-Compliant Flow Electroporation^®

Watch MaxCyte researcher Isabel Daher present on optimizing VLP manufacturing for high yields in HEK cells using MaxCyte’s Flow Electroporation platform.

Thumbnail of Efficient Large-Scale, Virus-Like Particle Manufacturing for Gene Editing poster

Scientific Poster/Poster Presentation

Virus-like Particles

CRISPR/Gene Editing

HEK293

T Cells

Efficient, Large-Scale Virus-Like Particle Manufacturing for Gene Editing by a GMP-Compliant Flow Electroporation Platform

The ExPERT GTx^® efficiently manufactured clinical-scale VLPs in adherent and suspension HEK cells, packaged with CRISPR-Cas9 or adenine base editor RNPs, for genome editing in primary human cells.

Poster thumbnail for Optimizing Transposon-Based Gene Delivery

Scientific Poster/Poster Presentation

Cell Therapy

TCR/CAR T

T Cells

Optimizing Transposon-Based Gene Delivery for Cell Therapy Applications with the MaxCyte^® ExPERT Scalable Electroporation Platform

MaxCyte electroporation efficiently engineered primary human T cells with piggyBac transposons to express CARs, while maintaining high cell viabilities, cell yields and functionality.

Pages: 12345678910111213141516171819202122

Peer Reviewed Publications Featuring MaxCyte Electroporation

<span class="arrow-icon">View Publications</span>

Featured Science

<span class="arrow-icon">View Featured Science</span>

Resource Library

Filter by

Resource type

Application

Cell type

MaxCyte Electroporation Enables the Production of Assay-Ready Cells Suitable for Ion Channel Studies

SeQure DX™ Risk Assessment Services Align with FDA Guidance for Gene-Edited Human Gene Therapy Products

Rethinking Partnerships in Cell & Gene Therapy—How MaxCyte’s Business Model Drives Real Results

Optimizing CRISPR/Cas-Mediated CAR Knockin in Primary Human T Cells Using MaxCyte Electroporation

Combining CRISPR & Transposon-Based Technologies for Improved sdAb-Based CAR T Therapies

Scalable Electroporation Optimizes Transposon Delivery in CAR T Cell Manufacturing Workflows

MaxCyte Electroporation Enables CRISPR/Cas-Mediated CAR Knockin in Primary Human T cells

Optimizing VLP Manufacturing for Gene Editing by GMP-Compliant Flow Electroporation^®

Efficient, Large-Scale Virus-Like Particle Manufacturing for Gene Editing by a GMP-Compliant Flow Electroporation Platform

Optimizing Transposon-Based Gene Delivery for Cell Therapy Applications with the MaxCyte^® ExPERT Scalable Electroporation Platform

Peer Reviewed Publications Featuring MaxCyte Electroporation

Featured Science

Receive upcoming events, new resources and more in your inbox

Cell Therapy

Gene Editing

Protein & Antibody Production

Cell Based Assays

Viral Vector

Vaccine Development

Industries

Cell & Gene Therapy

Discovery & Translational Research

Bioprocessing

Resource Library

Filter by

Resource type

Application

Cell type

MaxCyte Electroporation Enables the Production of Assay-Ready Cells Suitable for Ion Channel Studies

SeQure DX™ Risk Assessment Services Align with FDA Guidance for Gene-Edited Human Gene Therapy Products

Rethinking Partnerships in Cell & Gene Therapy—How MaxCyte’s Business Model Drives Real Results

Optimizing CRISPR/Cas-Mediated CAR Knockin in Primary Human T Cells Using MaxCyte Electroporation

Combining CRISPR & Transposon-Based Technologies for Improved sdAb-Based CAR T Therapies

Scalable Electroporation Optimizes Transposon Delivery in CAR T Cell Manufacturing Workflows

MaxCyte Electroporation Enables CRISPR/Cas-Mediated CAR Knockin in Primary Human T cells

Optimizing VLP Manufacturing for Gene Editing by GMP-Compliant Flow Electroporation®

Efficient, Large-Scale Virus-Like Particle Manufacturing for Gene Editing by a GMP-Compliant Flow Electroporation Platform

Optimizing Transposon-Based Gene Delivery for Cell Therapy Applications with the MaxCyte® ExPERT Scalable Electroporation Platform

Peer Reviewed Publications Featuring MaxCyte Electroporation

Featured Science

Receive upcoming events, new resources and more in your inbox

Cell Therapy

Gene Editing

Protein & Antibody Production

Cell Based Assays

Viral Vector

Vaccine Development

Industries

Cell & Gene Therapy

Discovery & Translational Research

Bioprocessing

Optimizing VLP Manufacturing for Gene Editing by GMP-Compliant Flow Electroporation^®

Optimizing Transposon-Based Gene Delivery for Cell Therapy Applications with the MaxCyte^® ExPERT Scalable Electroporation Platform